Metabolic syndrome - dysregulation of adipose tissue endocrine function
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
25246153
PII: 49586
Knihovny.cz E-zdroje
- MeSH
- adipokiny metabolismus MeSH
- diabetes mellitus 2. typu etiologie MeSH
- energetický metabolismus fyziologie MeSH
- inzulin metabolismus MeSH
- inzulinová rezistence MeSH
- lidé MeSH
- metabolický syndrom patofyziologie MeSH
- signální transdukce fyziologie MeSH
- tuková tkáň patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- adipokiny MeSH
- inzulin MeSH
Metabolic syndrome, acondition increasing cardiovascular morbidity, mortality and risk for diabetes mellitus type 2, is currently worldwide reaching epidemic proportions. This complex disorder represents an urgent challenge for new pharmacotherapeutic strategies formulation. Pathophysiological mechanisms underlying metabolic syndrome are not completely understood, nevertheless growing evidence is supporting the hypothesis that multiple metabolic dysregulations do contribute to its development. Apotential target for pharmacological intervention is considered to be dysregulation of adipose tissue endocrine/paracrine function. Specific adipokines, proteins secreted by the adipose tissue, with some pleiotropic effects, have been identified with strong association to regulation of energy metabolism, appetite, insulin signaling, tissue insulin sensitivity and the proinflammatory state related to metabolic syndrome. The aim of this paper is to provide a brief overview of endocrine/paracrine functions of the adipose tissue with regard to metabolic syndrome development and pathophysiology and particular adipokines as potential targets for innovative pharmacotherapeutic approaches.